Gubra A/S raised financial guidance for full-year 2023. For the period, organic revenue growth is now expected to be 16-21% (previously around 10%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
311 DKK | -2.81% | +4.01% | +148.80% |
04-17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
03-29 | Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. | CI |
1st Jan change | Capi. | |
---|---|---|
+148.80% | 756M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- GUBRA Stock
- News Gubra A/S
- Gubra A/S Raises Financial Guidance for Full-Year 2023